MA27775A1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA27775A1
MA27775A1 MA28583A MA28583A MA27775A1 MA 27775 A1 MA27775 A1 MA 27775A1 MA 28583 A MA28583 A MA 28583A MA 28583 A MA28583 A MA 28583A MA 27775 A1 MA27775 A1 MA 27775A1
Authority
MA
Morocco
Prior art keywords
compounds
organic compounds
preparing
formula
treatment
Prior art date
Application number
MA28583A
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Brian Cox
Urs Baettig
Gurdip Bhalay
Nicholas James Devereux
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27775(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27775A1 publication Critical patent/MA27775A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des composés représentés par la formule (I) sous forme de sel ou de composés zwitterioniques, dans laquelle R1, R2, R3, et R4 ont la signification indiquée dans le descriptif, convenant pour le traitement de manifestations induites par le récepteur muscarinique de type M3. Sont également décrites des compositions pharmaceutiques contenant lesdits composés et une méthode de préparation de ces composés.
MA28583A 2003-05-02 2005-11-08 Composes organiques MA27775A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
MA27775A1 true MA27775A1 (fr) 2006-02-01

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28583A MA27775A1 (fr) 2003-05-02 2005-11-08 Composes organiques

Country Status (31)

Country Link
US (2) US20070060563A1 (fr)
EP (1) EP1631569B1 (fr)
JP (1) JP4416786B2 (fr)
KR (1) KR100896544B1 (fr)
AR (1) AR044134A1 (fr)
AT (1) ATE440840T1 (fr)
AU (1) AU2004234069B2 (fr)
BR (1) BRPI0410238A (fr)
CA (1) CA2523436C (fr)
CL (1) CL2004000918A1 (fr)
CO (1) CO5700782A2 (fr)
CY (1) CY1109655T1 (fr)
DE (1) DE602004022805D1 (fr)
DK (1) DK1631569T3 (fr)
EC (1) ECSP056134A (fr)
ES (1) ES2331185T3 (fr)
HR (1) HRP20050933A2 (fr)
IL (1) IL171591A (fr)
IS (1) IS2746B (fr)
MA (1) MA27775A1 (fr)
MX (1) MXPA05011739A (fr)
MY (1) MY142652A (fr)
NO (1) NO20055688L (fr)
NZ (1) NZ542995A (fr)
PE (1) PE20050465A1 (fr)
PL (1) PL1631569T3 (fr)
PT (1) PT1631569E (fr)
RU (1) RU2363700C2 (fr)
SI (1) SI1631569T1 (fr)
TW (1) TWI340139B (fr)
WO (1) WO2004096800A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE555111T1 (de) * 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
EP1950196A1 (fr) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de fabrication d'hexafluorophosphates d'ammonium
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
EA017627B1 (ru) * 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (fr) * 2008-06-17 2009-12-23 Argenta Discovery Limited Dérivés de 1-aza-bicyclo [2.2.2] octane utiles en tant qu’antagonistes des récepteurs muscariniques
BR112012032332A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
BR112014013179A2 (pt) * 2011-12-30 2017-06-13 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica e usos de um composto
WO2013166413A2 (fr) * 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions et procédés pour augmenter des peptides neurotrophiques
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1302458A4 (fr) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd Derives d'ester
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
PT1631569E (pt) 2009-11-26
RU2005137360A (ru) 2006-07-27
US20070060563A1 (en) 2007-03-15
AR044134A1 (es) 2005-08-24
MY142652A (en) 2010-12-15
AU2004234069A1 (en) 2004-11-11
US20100041887A1 (en) 2010-02-18
IL171591A (en) 2010-11-30
CA2523436A1 (fr) 2004-11-11
EP1631569B1 (fr) 2009-08-26
JP4416786B2 (ja) 2010-02-17
ECSP056134A (es) 2006-04-19
HRP20050933A2 (en) 2006-12-31
TWI340139B (en) 2011-04-11
CY1109655T1 (el) 2014-08-13
IS8158A (is) 2005-11-30
KR20060015572A (ko) 2006-02-17
JP2006525267A (ja) 2006-11-09
AU2004234069B2 (en) 2008-02-21
PL1631569T3 (pl) 2010-02-26
TW200505920A (en) 2005-02-16
BRPI0410238A (pt) 2006-05-16
CA2523436C (fr) 2011-11-01
NO20055688D0 (no) 2005-12-01
CO5700782A2 (es) 2006-11-30
US8168654B2 (en) 2012-05-01
CL2004000918A1 (es) 2005-02-11
NZ542995A (en) 2009-02-28
ES2331185T3 (es) 2009-12-23
SI1631569T1 (sl) 2010-01-29
KR100896544B1 (ko) 2009-05-07
WO2004096800A2 (fr) 2004-11-11
HK1087704A1 (en) 2006-10-20
RU2363700C2 (ru) 2009-08-10
NO20055688L (no) 2006-01-09
DK1631569T3 (da) 2009-11-23
IS2746B (is) 2011-08-15
EP1631569A2 (fr) 2006-03-08
ATE440840T1 (de) 2009-09-15
MXPA05011739A (es) 2006-01-26
WO2004096800A3 (fr) 2005-01-06
PE20050465A1 (es) 2005-07-18
DE602004022805D1 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
MA27775A1 (fr) Composes organiques
MA31766B1 (fr) Composés organiques
MA28747B1 (fr) Dérivés de pyridine
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA31373B1 (fr) Composes amino-heterocycliques
TN2009000450A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA28007A1 (fr) Composes organiques
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
TNSN05250A1 (fr) Pyrimidinones substituees
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
TN2011000316A1 (fr) Derives de sulfonamides
MA31754B1 (fr) Cis-imidazolines chirales
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA30532B1 (fr) Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
MA34308B1 (fr) Triazolopyridines substituées